Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovaleucel + Chemotherapy in Advanced NPC
NCT02578641Phase 3Completed
- Sponsor
- Tessa Therapeutics
- Start
- Jul 2014
- Primary completion
- Feb 2022
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 5
01
Overview
A Phase 3 trial of Rovaleucel in nasopharyngeal carcinoma (NPC), sponsored by Tessa Therapeutics. Started Jul 2014; status: completed.
02
Drugs
Rovaleucel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02578641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578641.